Low-dose aspirin appears to reduce liver fat, slow the progression of scarring, and lower the risk of liver cancer in people with fatty liver disease. The strongest single piece of evidence is a 2024 randomized clinical trial published in JAMA, which found that six months of daily low-dose aspirin cut liver fat content while a placebo group saw theirs increase. But the connection runs deeper than one trial, touching on how platelets drive liver inflammation, how aspirin changes fat metabolism inside liver cells, and why the benefit may depend on your sex, your gut health, and how long you take the drug.
A Randomized Trial Showed Aspirin Can Shrink Liver Fat
For years, the link between aspirin and fatty liver came almost entirely from observational studies, where it is hard to separate aspirin’s effect from the habits and health conditions of people who take it. That changed with a randomized, placebo-controlled trial of patients with metabolic dysfunction-associated steatotic liver disease (the updated name for what most people still call fatty liver). In the aspirin group, the average liver fat content dropped, while the placebo group saw an increase. The difference was not subtle. Measured by magnetic resonance spectroscopy, the aspirin group experienced a mean reduction in liver fat of about 6.6 percentage points, while the placebo group gained roughly 3.6 points, resulting in roughly a ten-point gap between the two groups. More than 40% of aspirin-treated patients achieved at least a 30% relative reduction in liver fat, compared with about 12.5% on placebo.1PubMed Central. Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial
This trial was relatively small, with 80 participants, and ran for only six months. Those are real limitations. But because it was randomized and placebo-controlled, it provides the kind of cause-and-effect evidence that observational data cannot. The question now is whether larger, longer trials confirm the finding and whether the benefit extends to harder outcomes like cirrhosis or liver failure, not just fat on an MRI scan.
How Aspirin Acts on the Liver
Aspirin is best known for blocking an enzyme called COX-1 in platelets, which is why a baby aspirin a day can prevent blood clots. But inside the liver, that same mechanism has wider consequences. Platelets are not just passive bystanders in liver disease. When they accumulate in the liver and become activated, they release signals that drive inflammation. Aspirin blocks that activation, and preclinical research shows this reduces intrahepatic platelet accumulation and dials down the inflammatory response.2Biomedicine & Pharmacotherapy. Aspirin reprograms platelet signaling and the intrahepatic microbiome to suppress RyR2-driven inflammation and fibrosis in preclinical chronic liver disease Aspirin also inhibits a key inflammatory signaling pathway (NF-κB) in Kupffer cells, the resident immune cells of the liver, reducing the production of inflammatory molecules that push liver disease forward.3PubMed Central. Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks
Beyond inflammation, aspirin seems to influence how the liver handles fat. Cell-based experiments have shown that aspirin boosts the burning of long-chain fatty acids inside mitochondria, the energy-producing compartments of cells. The effect appears to work not by revving up the enzymes that burn fat directly, but by increasing the transport of fatty acids into mitochondria in the first place.4PubMed Central. Aspirin Increases Mitochondrial Fatty Acid Oxidation Separately, animal and cell studies have found that aspirin activates a signaling chain that simultaneously dials down fat production in liver cells and ramps up the metabolic pathways that break fat down. In rabbits fed a high-cholesterol diet, aspirin treatment reduced lipid accumulation in liver tissue and improved markers like triglycerides and the liver enzyme ALT.5PubMed Central. Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions
Put together, the picture is one of aspirin hitting fatty liver from multiple directions: cooling inflammation, quieting immune cells, and nudging the liver to burn fat rather than store it. No single mechanism fully explains the effect, which is part of why it took so long for researchers to recognize aspirin’s potential in liver disease.
Slowing Fibrosis and Scarring
Fat in the liver is a problem, but the real danger comes when that fat triggers chronic inflammation that leads to fibrosis, the gradual replacement of healthy tissue with scar tissue. If fibrosis progresses far enough, it becomes cirrhosis, which can cause liver failure. Aspirin appears to slow that progression at a cellular level by suppressing the activation of hepatic stellate cells, the cells that produce scar tissue when they are switched on by inflammation. Lab studies have shown aspirin inhibits both the activation and proliferation of these cells, leading to lower levels of inflammatory signals like IL-6 and TNF-α.6PubMed Central. Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4/NF-κB pathway
These lab findings line up with what clinicians see in patients. A U.S. cross-sectional study using national health survey data found that aspirin users had significantly lower scores on four standard, non-invasive fibrosis indices compared with non-users. The association was stronger in people who already had signs of chronic liver disease than in those who did not, suggesting aspirin’s anti-fibrotic effect matters most in the people who need it most.7PubMed. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States In a smaller clinical study of diabetic patients with fatty liver disease, adding low-dose aspirin to standard treatment for six weeks was linked to significantly lower fibrosis marker scores compared with standard treatment alone.8Aposta: Revista de Ciencias Sociales. Role of aspirin in slowing the progression of hepatic fibrosis in diabetic patients with metabolic-associated fatty liver dysfunction
A word of caution: fibrosis scores are estimates based on blood tests, not direct measurements of scar tissue. They are useful screening tools but imperfect. Still, the consistency across lab, animal, and human data is encouraging enough that researchers are designing larger trials to see if aspirin can meaningfully prevent cirrhosis.
Liver Cancer Protection
Fatty liver disease, especially when it progresses to cirrhosis, is a growing cause of hepatocellular carcinoma, the most common form of primary liver cancer. A large body of observational evidence now links aspirin use to a lower risk of developing this cancer, and the association appears to be dose- and duration-dependent.
A Swedish nationwide cohort study that followed patients with chronic liver disease for a median of nearly eight years found that aspirin users had a cumulative liver cancer incidence of about 4.0%, compared with 8.3% for non-users. The benefit grew stronger with longer use. Compared with short-term use, five or more years of aspirin was associated with roughly a 40% further reduction in risk.9PubMed Central. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality A separate large cohort study focused specifically on patients with fatty liver disease found similar results, with aspirin-treated patients showing roughly half the ten-year risk of liver cancer compared with untreated patients.10The Lancet Gastroenterology & Hepatology. Daily low-dose aspirin therapy is associated with a reduced risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a nationwide cohort study
A meta-analysis pooling cohort studies covering roughly 2.5 million people found that aspirin use was associated with about a 30% reduced risk of liver cancer overall.11PubMed Central. The Effect of Aspirin Use on Incident Hepatocellular Carcinoma—An Updated Systematic Review and Meta-Analysis A U.S. prospective study added more granularity, finding that regular use of standard-dose aspirin at least twice weekly was needed to see a clear benefit. Taking it for five or more years at that frequency was associated with the strongest risk reduction.12JAMA Oncology. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma
All of this remains observational. People who take aspirin regularly tend to be engaged with the health-care system, which introduces bias. But the consistency of the association across different populations, study designs, and countries, combined with the plausible biological mechanisms discussed above, makes this one of the more compelling findings in liver cancer prevention research.
The Gut Barrier Complication
If aspirin were purely helpful for the liver, the research picture would be simpler. But the gut and the liver are deeply connected through the portal vein, which carries everything absorbed from the intestines straight to the liver. Anything that disrupts the gut lining can send bacterial toxins into the liver and fuel inflammation there.
NSAIDs, including aspirin, are well known to damage the gut lining. A review of the relationship between NSAIDs and intestinal permeability explained that these drugs undergo a recycling process between the liver and gut that exposes the intestinal lining to repeated contact. This can weaken the tight junctions between gut cells, allow bacteria and their toxic products to leak into the portal bloodstream, and trigger a liver inflammatory response. In people already at risk due to obesity or metabolic syndrome, this leaky-gut effect could potentially promote rather than prevent fatty liver progression.13PubMed Central. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease
More recent research has identified specific changes aspirin makes to the gut microbiome. A study in both humans and mice found that low-dose aspirin reduced the abundance of a beneficial gut bacterium, Parabacteroides goldsteinii, that plays a role in maintaining gut barrier integrity and producing protective bile acids. When the researchers transplanted this bacterium back into aspirin-treated mice, it restored the bile acid pool and protected against aspirin-induced intestinal damage.14Cell Host & Microbe. Low-dose aspirin disturbs intestinal homeostasis by suppressing Parabacteroides goldsteinii and its bile acid metabolite 7-keto-lithocholic acid
This creates a genuine tension in the evidence. Aspirin may help the liver directly through anti-inflammatory and fat-burning pathways while simultaneously harming it indirectly through the gut. How these competing effects balance out in a given person likely depends on the health of their gut microbiome, their diet, their body weight, and the dose and duration of aspirin use. Researchers are only beginning to untangle this.
Sex Differences Seen in Animal Studies
One of the more provocative findings in this area comes from a mouse study examining whether low-dose aspirin could prevent obesity and fatty liver in offspring exposed to excess nutrition before birth. The results split sharply along sex lines. Female mice given aspirin lost weight, reversed glucose intolerance, and showed reduced fat accumulation in the liver. Male mice given the same dose did not see any of these benefits. The female mice showed re-sensitized insulin signaling and activated energy-sensing pathways in the liver, along with changes in tumor-suppressor gene regulation. The males showed a completely different pattern of molecular responses that did not translate into metabolic improvement.15PubMed Central. Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero
Mouse studies do not automatically translate to humans, and this experiment used a specific model of developmental over-nutrition that may not be representative of adult fatty liver disease. But the finding raises a question worth watching: could aspirin’s liver benefits differ between men and women? Hormonal differences affect liver metabolism in well-documented ways, and sex-stratified analyses in future human trials would help answer whether the treatment works equally well for everyone.
How Aspirin Compares to Other Anti-Inflammatory Drugs
If aspirin helps the liver partly by reducing inflammation, you might wonder whether other anti-inflammatory painkillers do the same. The evidence suggests they do not, and some may do the opposite. A large epidemiological study found that current use of non-aspirin NSAIDs (drugs like ibuprofen and naproxen) was actually associated with a roughly 29% higher risk of developing fatty liver disease, while acetaminophen showed no significant association in either direction.16PubMed. Association between aspirin use and the risk of incident nonalcoholic fatty liver disease This suggests aspirin’s liver benefits go beyond generic anti-inflammatory effects and involve pathways specific to its unique mechanism of action, particularly its irreversible modification of COX-1 in platelets and its direct effects on liver cell metabolism.
When it comes to liver cancer, the picture is more nuanced. A systematic review found that aspirin reduced the risk of new liver cancer, while for preventing cancer recurrence after treatment, non-aspirin NSAIDs showed a significant benefit but aspirin alone did not reach statistical significance.17PubMed. Systematic review with meta-analysis: The effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma The reasons for this split are not entirely clear, though it may reflect the different molecular targets these drugs hit or simply the limited data available on recurrence.
Bleeding Risk in Practice
Any conversation about aspirin for fatty liver has to reckon with bleeding. The same mechanism that makes aspirin useful against clots and inflammation also makes you more likely to bleed, especially from the gastrointestinal tract. The meta-analysis of aspirin and liver cancer found a small but real increase in gastrointestinal bleeding events among aspirin users, with an odds ratio of about 1.3.17PubMed. Systematic review with meta-analysis: The effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma That risk is higher in people with advanced liver disease, who already tend to have clotting problems due to reduced production of clotting factors by a damaged liver. Patients with established cirrhosis and portal hypertension, which can cause dilated veins in the esophagus or stomach, face a particularly delicate risk-benefit calculation.
For the majority of people with early-stage fatty liver, though, the bleeding risk from a standard low-dose aspirin (75 to 100 mg daily) is modest and well-characterized from decades of cardiovascular research. The randomized trial discussed earlier reported no serious bleeding events in its aspirin group over six months. The bigger practical question is whether your doctor would prescribe aspirin specifically for fatty liver disease today. As of now, no major liver society has issued guidelines recommending aspirin for this purpose. The evidence is building, but it has not yet crossed the threshold where it changes standard clinical practice.
How Aspirin Is Processed When the Liver Is Already Compromised
People with liver disease sometimes worry that their liver cannot handle aspirin properly, which could lead to toxic buildup. A pharmacokinetic study comparing aspirin metabolism in young adults, elderly adults, and patients with alcoholic liver disease found that most measures of how the body processes aspirin and its main breakdown product, salicylate, did not differ significantly across these groups. The main factor affecting how quickly salicylate was cleared from the blood was not liver disease itself but individual levels of blood albumin, the protein that salicylate binds to in the bloodstream.18PubMed. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease People with severe liver disease tend to have low albumin, which can increase the free, active fraction of salicylate in the blood. This does not mean aspirin is unsafe in all liver disease, but it does mean that anyone with significantly impaired liver function needs closer medical monitoring.
Adherence Patterns Among People with Liver Disease
Even when a drug works in a trial, real-world benefit depends on whether patients actually take it consistently. A nationwide Danish cohort study looking at antithrombotic drug use found something counterintuitive: patients with liver disease were slightly more adherent to aspirin than patients without liver disease, with about 36% maintaining adherence versus roughly 32% in the general population.19The Lancet Regional Health – Europe. Antithrombotic prescribing, adherence, persistence, and associated clinical outcomes in patients with liver disease: a nationwide population-based cohort study Those absolute numbers are low on both sides, which reflects a well-known pattern across chronic medications. But the finding that liver disease does not appear to reduce aspirin adherence is reassuring for researchers designing longer-term trials, since dropout and non-compliance can undermine even the most promising intervention. One possible explanation is that patients with a known liver diagnosis may be more motivated to follow their medication regimens, though the study did not test that directly.